PTAB upholds Seer patent for nano- and microparticles in challenge by Bruker

Seer (SEER) announced that the Patent Trial and Appeal Board, or PTAB, of the U.S. Patent and Trademark Office issued a Final Written Decision on March 23 in an inter partes review of U.S. Patent No. 11,435,360 B2. The inter partes review was filed by PreOmics and Biognosys, each a subsidiary of Bruker (BRKR), challenging 11 of 29 claims of the ‘360 Patent. The ‘360 patent covers methods for analyzing biological samples using engineered nano- and microparticles that form protein coronas, resulting in protein enrichment that underlies Seer’s Proteograph platform for deep proteomic analysis. The ‘360 Patent is owned by The Brigham and Women’s Hospital, Inc. and is exclusively licensed to Seer. A total of 23 claims, including five challenged claims and 18 unchallenged claims, remain valid and protect Seer’s nanoparticle protein enrichment technology for analyzing biological samples, including cells, tissues and biofluids. The upheld claims are directed to detecting proteins across a wide concentration range and to particle-related aspects of Seer’s technology, both of which enable deep proteomic analysis.